(MBOT) Microbot Medical - Ratings and Ratios

Microbot Medical Inc. (NASDAQ:MBOT) is a pre-clinical medical device company specializing in the development of robotic systems for endoluminal surgery. The company focuses on advancing minimally invasive surgical technologies, addressing unmet needs in cardiovascular, peripheral, and neurovascular interventions. Its lead product, LIBERTY, is a robotic surgical system designed to enable remote catheter-based procedures, reducing radiation exposure, physical strain, and infection risks for physicians. LIBERTY is currently in pre-clinical stages and aims to enhance precision and accessibility in vascular surgeries. Microbot also owns NovaCross, a patented technology for intraluminal revascularization with an integrated anchoring mechanism and microcatheter, targeting complex vascular blockages. The company has established strategic partnerships, including a co-development agreement with Stryker Corporation and a Phase 2 collaboration with Corewell Health to advance LIBERTY. Founded in 2010 and headquartered in Braintree, Massachusetts, Microbot Medical is positioned as an innovator in the robotic medical device sector, with a focus on improving outcomes in minimally invasive procedures.

Microbot Medical Inc. operates in the high-growth health care equipment industry, with a market capitalization of $51.42 million. The company is listed on the NASDAQ under the ticker symbol MBOT. Its stock has shown volatility, with a 20-day average volume of 3,278,706 shares and a last price of $1.40. Technical indicators suggest a challenging near-term outlook, with the stock trading below its 20-day and 50-day simple moving averages of $1.80 and $1.73, respectively. The 200-day SMA of $1.17 indicates a longer-term downtrend. The Average True Range (ATR) of $0.31 reflects moderate volatility. On the fundamental side, the companys price-to-book ratio of 14.32 highlights elevated valuations relative to book value, while the absence of P/E and P/S metrics underscores its pre-revenue stage. With no reported return on equity (RoE), the company remains focused on R&D and commercialization efforts.